Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
Oak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow Read More »
